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Excess cardiac and vascular disease ‘complicates’ Type-2 diabetes (T2DM) before diagnosis. 
Aortic pulse wave velocity (PWV) powerfully predicts mortality in those with and at risk of 
T2DM independent of blood pressure (BP) (1). We tested the hypothesis that spironolactone, 
dietary nitrate or both could reduce PWV as a treatment target formally independent of BP in 
a 6-month, double-blind, parallel, randomized controlled (RCT), 2x2 factorial trial.  
Participants with or at risk of T2DM (n=126, 57±12 years) were randomized to 
spironolactone (12.5mg titrated to 25mg, twice daily) or doxazosin (4-8mg, twice daily) and 
dietary nitrate as ‘Beet-it’ beetroot juice (7.5mmol nitrate increased to 11.2mmol) or nitrate-
free ‘Beet-it’ juice, a specific placebo (2). Outcomes were primarily change in arterial 
stiffness as cardio-ankle vascular index (CAVI), a nominally BP-independent measure, 
secondarily aortic PWV by Arteriograph, with other haemodynamic parameters measured.  
Outcomes were adjusted for peripheral BP differences at baseline and BP change between 
trial arms from the trial’s start to end, analyzed by modified ‘intention-to-treat’.  CAVI0, a 
measure arguably more reliably BP independent, was also calculated (3). Data are least-
square means from mixed effects models adjusted as pre-specified. No statistical interactions 
occurred between the ‘juice’ and ‘drug’ arms.  
Spironolactone and doxazosin reduced systolic BP similarly (mean[95% CI]: -7.0[-9.9,-4.2] 
vs. -6.3[-9.1,-3.5]mmHg, p=0.7). Reductions were borderline in CAVI and significant for 
aortic PWV towards doxazosin not spironolactone, contrary to our hypothesis; CAVI0 data 
yielded a non-significant difference (Table 1). 
The change in systolic BP was no different in the active versus placebo beetroot juice (-6.4[-
9.2,-3.6] vs. -6.9[-9.8,-4.0]mmHg respectively, p=0.8). There were also no differences in 
change in CAVI (p=0.98) nor aortic PWV p=0.8 (Table 1). However, the difference in 
change in central systolic BP between active and placebo juices was highly significant -2.6[-
4.5,-0.75]mmHg, p=0.007; differences in change of central and brachial augmentation index, 
other indices of arterial function that are prognostic, were borderline. 
 
Table 1. Difference in change from baseline for CAVI and aortic PWV between 
treatmentsa 
 CAVI CAVI0 Aortic PWV 
Spironolactone vs. doxazosin 0.25(-0.03, 0.53) 0.28(-0.30, 0.87) 0.37(0.01, 0.73) 
P 0.080 0.34 0.045                                                          
Beetroot juice vs. placebo juice 0.0(-0.28, 0.29) 1.03(0.98, 1.08) 0.05(-0.31, 0.41) 
P 0.98 0.38 0.79 
Data are mean(95% confidence intervals). 
CAVI, cardio-ankle vascular index; CAVI0, cardio-ankle vascular index adjusted for BP (3); PWV, pulse wave 
velocity  
aAdjusted for baseline and difference in systolic blood pressure (BP) change between the arms analyzed. Aortic 
PWV were also adjusted for change in systolic BP. Least square mean data were averaged over follow-up visits 
(3 and 6 months).  
 
This trial suggests a proof of concept that arterial stiffness, an independent predictor of 
mortality generally and in T2DM (1), can be altered independently of BP, as measured by 
CAVI and particularly aortic PWV, if rather borderline and not as hypothesized. Clearly, 
detecting such change in direction of both PWV and CAVI would be underpowered. Cardiac 
function may have become impaired on doxazosin, as found in the ALLHAT trial, 
specifically in people with T2DM. Our results contrast with previous work in the Journal, in 
patients with mild kidney impairment, which suggested spironolactone at 25mg reduced 
PWV by 0.8m/s, but that was compared against placebo (4), whereas active BP-lowering was 
intentionally controlled for using the interventions in this study.  
Despite no changes in CAVI, aortic PWV or peripheral BP in the nitrate arm, plasma [nitrate] 
and [nitrite] increased 4-fold and 2-fold respectively, suggesting the nitrate-nitrite-nitric 
oxide pathway was not interrupted. The simultaneous selective decrease in central BP on 
nitrate-containing juice is entirely consistent with our previous findings of normoxia-
dependent conduit artery dilatation after inorganic nitrite, selectively reducing central BP (5).  
In conclusion, these data show the potential of reducing arterial stiffening while controlling 
for BP change, although adds to the debate regarding the independence of CAVI from BP.  
Other shorter-term evidence is available that people with diabetes do not respond to inorganic 
nitrate with brachial BP-lowering, nor here with change in PWV either; however, central BP 
is responsive.  The search remains for therapeutic agents that reduce PWV safely and 
effectively, combined with reducing BP.  
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